EBMT 2017 | Advantages of chemotherapy and hypomethylating agents in myelodysplastic syndrome
Maria Teresa Voso
• 26 Mar 2017
Maria Teresa Voso, MD, from University Tor Vergata Rome, Rome, Italy, discusses the use of conventional chemotherapy and hypomethylating agents before allogeneic hematopoietic stem cell transplant (HSCT) at the 2017 annual meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Marseille, France. She explains that a large proportion of patients can undergo HSCT, but that a bridging treatment may be required while this is organized. Dr Voso discusses which patient subgroups may most benefit from hypomethylating agents and chemotherapy, but concludes that the two treatments need to be compared in a randomized prospective study.
